|
||
| |||||||
|
Introduction While the mild to moderate Alzheimer’s disease (AD) market grew strongly over 2002 to exceed $1.5 billion, drug manufacturers are now recognizing opportunities in other areas of the dementia population. Of particular interest is the treatment of mild cognitive impairment (MCI), treatment of severe AD, and treatment of vascular dementia. Scope Epidemiology: including prevalence split by the seven major markets, diagnosis rates, and treatment rates Analysis of unmet needs as identified by opinion leaders Discussion of current drug treatments Analysis of drugs in late stage development for these areas, including Aricept, Exelon, Reminyl and memantine Report Highlights There are no approved drugs for MCI, VaD with only memantine approved for severe AD in the EU. Companies currently manufacturing of AD products, Aricept, Exelon and Reminyl are expected to file NDA’s for treatment of MCI during 2004. Despite Aricept’s failure to gain FDA approval for VaD in July 2003, Datamonitor predicts it will be approved during 2005 and will experience the benefits of first to market status. Memantine is currently the only treatment approved for sever AD in the EU, and is expected to be launched in the US during 2004. Datamonitor predicts strong uptake in this niche market with see sales nearing blockbuster figures over the next 8 years. Reasons to Purchase Identify hot areas of the dementia and MCI market that are not being targeted by competitors Improve knowledge of important issues, such as neuroprotection, as identified by respected experts in these fields Increase future revenue potential of an MCI product by understanding what is needed to improve low diagnosis rates Publisher: Datamonitor CNS Central Nervous System Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a90 |
|
|
